Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Jacques Wils

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Activities & Behaviors

Drug Evaluation

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
11
Bleiberg, Harry
10
Blijham, Geert
8
Baron, Benoît
8
Van Cutsem, Eric
7
Paillot, Bernard
7
Conroy, Thierry
6
Couvreur, ML
6
Wals, Jacob
6
Schouten, Leo
5
Sahmoud, TM
5
Nordlinger, Bernard
5
Schouten, Harry
5
Erdkamp, F L G
5
Hupperets, Pierre
4
Jager, Jos

Sign-in to see all Coauthors

Publications

TOP 3
Lutz Manfred P; Wilke Hansjochen; Wagener D J Theo; Vanhoefer Udo; Jeziorski Krzysztof; Hegewisch-Becker Susanna; Balleisen Leopold; Joossens Eric; Jansen Rob L; Debois Muriel; Bethe Ullrich; Praet Michel; Wils Jacques; Van Cutsem Eric;
Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie.
Hospers G A P; Schaapveld M; Nortier J W R; Wils J; van Bochove A; de Jong R S; Creemers G J; Erjavec Z; de Gooyer D J; Slee P H Th J; Gerrits C J H; Smit J M; Mulder N H
Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer.
Nitti D; Wils J; Dos Santos J Guimaraes; Fountzilas G; Conte P F; Sava C; Tres A; Coombes R C; Crivellari D; Marchet A; Sanchez E; Bliss J M; Homewood J; Couvreur M L; Hall E; Baron B; Woods E; Emson M; Van Cutsem E; Lise M;
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Jacques Wils (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2007: Lutz Manfred P; Wilke Hansjochen; Wagener D J Theo; Vanhoefer Udo; Jeziorski Krzysztof; Hegewisch-Becker Susanna; Balleisen Leopold; Joossens Eric; Jansen Rob L; Debois Muriel; Bethe Ullrich; Praet Michel; Wils Jacques; Van Cutsem Eric;
Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(18):2580-5.
2006: Hospers G A P; Schaapveld M; Nortier J W R; Wils J; van Bochove A; de Jong R S; Creemers G J; Erjavec Z; de Gooyer D J; Slee P H Th J; Gerrits C J H; Smit J M; Mulder N H
Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(3):443-9.
2006: Nitti D; Wils J; Dos Santos J Guimaraes; Fountzilas G; Conte P F; Sava C; Tres A; Coombes R C; Crivellari D; Marchet A; Sanchez E; Bliss J M; Homewood J; Couvreur M L; Hall E; Baron B; Woods E; Emson M; Van Cutsem E; Lise M;
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(2):262-9.
2005: Lutz Manfred P; Van Cutsem Eric; Wagener Theo; Van Laethem Jean-Luc; Vanhoefer Udo; Wils Jacques A; Gamelin Eric; Koehne Claus H; Arnaud Jean P; Mitry Emmanuel; Husseini Faress; Reichardt Peter; El-Serafi Mustafa; Etienne Pierre-Luc; Lingenfelser Thomas; Praet Michel; Genicot Bruno; Debois Muriel; Nordlinger Bernard; Ducreux Michel P;
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9250-6.
2005: Köhne C-H; van Cutsem E; Wils J; Bokemeyer C; El-Serafi M; Lutz M P; Lorenz M; Reichardt P; Rückle-Lanz H; Frickhofen N; Fuchs R; Mergenthaler H-G; Langenbuch T; Vanhoefer U; Rougier P; Voigtmann R; Müller L; Genicot B; Anak O; Nordlinger B;
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(22):4856-65.
2005: Nordlinger Bernard; Rougier Philippe; Arnaud Jean-Pierre; Debois Muriel; Wils Jaques; Ollier Jean-Claude; Grobost Olivier; Lasser Philippe; Wals Jacob; Lacourt Jerome; Seitz Jean-François; Guimares dos Santos Jose; Bleiberg Harry; Mackiewickz Rémy; Conroy Thierry; Bouché Olivier; Morin Thierry; Baila Liliana; van Cutsem Eric; Bedenne Laurent
Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.
The lancet oncology 2005;6(7):459-68.
2004: Van Rijswijk R E N; Jeziorski K; Wagener D J Th; Van Laethem J-L; Reuse S; Baron B; Wils J;
Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: a phase II study of the EORTC GastroIntestinal Tract Cancer Cooperative Group.
European journal of cancer (Oxford, England : 1990) 2004;40(14):2077-81.
2003: Köhne C-H; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur M L; Schmoll H J;
Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(20):3721-8.
2003: Wils J; Blijham G H; Wagener Th; De Greve J; Jansen R L H; Kok T C; Nortier J W R; Bleiberg H; Couvreur M L; Genicot B; Baron B;
High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group.
European journal of cancer (Oxford, England : 1990) 2003;39(3):346-52.
2002: Van Cutsem E; Dicato M; Wils J; Cunningham D; Diaz-Rubio E; Glimelius B; Haller D; Johnston P; Kerr D; Koehne C H; Labianca R; Minsky B; Nordlinger B; Roth A; Rougier P; Schmoll H J
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001).
European journal of cancer (Oxford, England : 1990) 2002;38(11):1429-36.
2002: Conroy T; Etienne P L; Adenis A; Ducreux M; Paillot B; Oliveira J; Seitz J F; Francois E; Van Cutsem E; Wagener D J T; Kohser F; Daamen S; Praet M; Gorlia T; Baron B; Wils J;
Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(5):721-9.
2002: Wagener D J T; Wils J A; Kok T C; Planting A; Couvreur M L; Baron B
Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial.
European journal of cancer (Oxford, England : 1990) 2002;38(5):648-53.
2002: Köhne C H; Cunningham D; Di Costanzo F; Glimelius B; Blijham G; Aranda E; Scheithauer W; Rougier P; Palmer M; Wils J; Baron B; Pignatti F; Schöffski P; Micheel S; Hecker H
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(2):308-17.
2001: Van Cutsem E; Dicato M; Wils J
Recent advances in the management of colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2001;37(18):2302-9.
2001: Peters F P; Fickers M M; Erdkamp F L; Wals J; Wils J A; Schouten H C
The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
Annals of hematology 2001;80(7):406-10.
2001: Peters F P; Lalisang R I; Fickers M M; Erdkamp F L; Wils J A; Houben S G; Wals J; Schouten H C
Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study.
Annals of hematology 2001;80(3):155-9.
2001: Hupperets P S; Wils J A; Volovics L; Schouten L J; Fickers M M; Bron H N; Jager J J; de Jong J M; Blijham G H
Adjuvant chemo-hormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate (MPA) for node-positive cancer patients, update at 12 years follow up.
Breast (Edinburgh, Scotland) 2001;10(1):35-7.
2001: Duffaud F; van der Burg M E; Namer M; Vergote I; Willemse PHB; ten Bokkel Huinink W; Guastalla J P; Nooij; Kerbrat P; Piccart M; Tumolo S; Favalli G; van der Vange N; Lacave A J; Wils J; Splinter T A; Einhorn N; Roozendaal K J; Rosso R; Vermorken J B
D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study.
Anti-cancer drugs 2001;12(2):159-62.
2000: Vanhoefer U; Rougier P; Wilke H; Ducreux M P; Lacave A J; Van Cutsem E; Planker M; Santos J G; Piedbois P; Paillot B; Bodenstein H; Schmoll H J; Bleiberg H; Nordlinger B; Couvreur M L; Baron B; Wils J A
Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(14):2648-57.
2000: Lalisang R I; Voest E E; Wils J A; Nortier J W; Erdkamp F L; Hillen H F; Wals J; Schouten H C; Blijham G H
Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer.
British journal of cancer 2000;82(12):1914-9.
2000: Wils J
Chemotherapy of metastatic gastric cancer.
Gan to kagaku ryoho. Cancer & chemotherapy 2000;27 Suppl 2():395-8.
1999: Wils J A; Bliss J M; Marty M; Coombes G; Fontaine C; Morvan F; Olmos T; Pérez-López F R; Vassilopoulos P; Woods E; Coombes R C
Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):1988-98.
1999: Wils J; van Geuns H; Stoot J; Bergmans M; Boschma F; Bron H; Degen J; Erdkamp F; van Erp J; Haest J; Iding R; Lalisang F; de Pree N; de Rooy C; Snijders M; Schepers J; Vreeswijk J; Wals J; Werter M; Wetzels L; Smeets J; Schouten L
Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic-IV ovarian cancer: a randomized phase III trial of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg.
Anti-cancer drugs 1999;10(3):257-61.
1999: Van Cutsem E; Cunningham D; Ten Bokkel Huinink W W; Punt C J; Alexopoulos C G; Dirix L; Symann M; Blijham G H; Cholet P; Fillet G; Van Groeningen C; Vannetzel J M; Levi F; Panagos G; Unger C; Wils J; Cote C; Blanc C; Hérait P; Bleiberg H
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
European journal of cancer (Oxford, England : 1990) 1999;35(1):54-9.
1998: Wils J; Sahmoud T; Sobrero A; Bleiberg H; Ahmedzai S; Blazeby J; Blijham G; Conroy T; Cunningham D; Curran D; Díaz-Rubio E; Ducreux M; Evans J; Glimelius B; Hutchinson G; Kerr D; Kiebert G; Köhne H; Labianca R; Langendijk R; Nitti D; Nordlinger B; Rougier P; Scheithauer W; Therasse P
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group.
Tumori 1998;84(3):335-47.
1998: Grimaldi C; Bleiberg H; Gay F; Messner M; Rougier P; Kok T C; Cirera L; Cervantes A; De Greve J; Paillot B; Buset M; Nitti D; Sahmoud T; Duez N; Wils J
Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(2):411-7.
1997: Bleiberg H; Gerard B; Wils J; Blijham G; Diaz-Rubio E; Herrmann R; Kerr D; Labianca R; Rougier P; Wilke H J; Wilking N
Gastrointestinal Tract Cancer Liaison Office: an attempt to organise clinical research in Europe.
European journal of cancer (Oxford, England : 1990) 1997;33(10):1536-45.
1997: Nitti D; Wils J; Sahmoud T; Curran D; Couvreur M L; Lise M; Rauschecker H; dos Santos J G; Stremmel W; Roelofsen F
Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group.
European journal of cancer (Oxford, England : 1990) 1997;33(8):1209-15.
1997: Wils J A; van Geuns H; Wals J; Vreeswijk J; Lalisang F
Efficacy of carboplatin plus primary prophylactic filgrastim (granulocyte colony stimulating factor) in relapsed ovarian cancer: a study of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg.
Anti-cancer drugs 1997;8(5):432-5.
1997: Schouten L J; Hupperets P S; Jager J J; Volovics L; Wils J A; Verbeek A L; Blijham G H
Prognostic significance of etiological risk factors in early breast cancer.
Breast cancer research and treatment 1997;43(3):217-23.
1997: Lalisang R I; Wils J A; Nortier H W; Burghouts J T; Hupperets P S; Erdkamp F L; Schouten H C; Blijham G H
Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(4):1367-76.
1996: Blijham G; Wagener T; Wils J; de Greve J; Buset M; Bleiberg H; Lacave A; Dalmark M; Selleslag J; Collette L; Sahmoud T
Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(8):2266-73.
1996: Wagener D J; Hoogenraad W J; Rougier P; Lusinchi A; Taal B G; Veenhof C H; de Graeff A; Conroy T; Curran D; Sahmoud T; Wils J
Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study.
European journal of cancer (Oxford, England : 1990) 1996;32A(8):1310-3.
1996: Coombes R C; Bliss J M; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López F R; Vassilopoulos P; Ferreira E P; Chilvers C E; Coombes G; Woods E M; Marty M
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):35-45.
1996: Conroy T; Etienne P L; Adenis A; Wagener D J; Paillot B; François E; Bedenne L; Jacob J H; Seitz J F; Bleiberg H; Van Pottelsberghe C; Van Glabbeke M; Delgado F M; Merle S; Wils J
Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):164-70.
1995: Hupperets P; Wils J; Volovics L; Schouten L; Fickers M; Bron H; Schouten H; Jager J; de Jong J; Beex L
Adjuvant chemo-hormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive cancer patients. Update at 7-year follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(1):90-1.
1994: Wils J; Bleiberg H; Rougier P
Adjuvant treatment of colon cancer. A plea for a large-scale European trial.
European journal of cancer (Oxford, England : 1990) 1994;30A(5):578-9; discussion 579-80.
1994: Leliefeld H; Wils J; Peulen G; Smeets J
Phase II study of orchiectomy combined with epirubicin as first-line treatment in advanced prostate carcinoma.
Cancer investigation 1994;12(4):395-8.
1993: Roelofs E J; Wagener D J; Conroy T; Wils J; Burghouts J T; Fickers M; de Graeff A; Lalisang F; Paillot B
Phase II study of sequential high-dose methotrexate (MTX) and 5-fluorouracil (F) alternated with epirubicin (E) and cisplatin (P) [FEMTX-P] in advanced gastric cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(5):426-8.
1993: Hupperets P S; Wils J; Volovics L; Schouten L; Fickers M; Bron H; Schouten H C; Jager J; Smeets J; de Jong J
Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(4):295-301.
1993: Conroy T; Wils J; Paillot B; Wagener D J; Burghouts J T; Fickers M M; de Graeff A; Lalisang F M
[Combination of 5-FU, high dose methotrexate, epirubicin and cisplatin (FEMTX-P protocol) in non surgical or locally recurrent metastatic gastric cancers]
Bulletin du cancer 1993;80(3):255-60.
1993: Stoot J; Wils J; von Geuns H; Smeets J; Schouten L
Chemotherapy consisting of cisplatin, epirubicin, and cyclophosphamide in advanced ovarian carcinoma. The Gynecologic Oncology Group of the Comprehensive Cancer Center, Limburg, The Netherlands.
Cancer investigation 1993;11(1):1-5.
1993: Wils J A
Mitoxantrone, leucovorin and high-dose infusional 5-fluorouracil: an effective and well-tolerated regimen for the treatment of advanced breast cancer.
European journal of cancer (Oxford, England : 1990) 1993;29A(15):2106-8.
1993: Wils J; Coombes R C; Marty M; Bliss J; Woods E
Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collaborative Cancer Group (ICCG).
Drugs 1993;45 Suppl 2():46-50; discussion 49-50.
1992: Delaere K P; Leliefeld H; Peulen F; Stapper E W; Smeets J; Wils J
Phase II study of epirubicin in advanced hormone-resistant prostatic carcinoma.
British journal of urology 1992;70(6):641-2.
1992: Wils J A
Role of chemotherapy in oesophageal carcinoma.
Pathologie-biologie 1992;39(9):929.
1992: Wils J; Wagener D J
Combined modality adjuvant treatment of high-risk rectal cancer: a treatment of choice or a choice of treatment?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(3):197-9.
1991: Wils J; Smeets J
Phase II study of cyclophosphamide (C), epirubicin (E), oncovin (O), prednisone (P), methotrexate (M) + leucovorin and bleomycin (B) (CEOP-MB) in intermediate and high grade non-Hodgkin lymphomas.
Journal of chemotherapy (Florence, Italy) 1991;3(4):260-3.
1991: Wils J A; Klein H O; Wagener D J; Bleiberg H; Reis H; Korsten F; Conroy T; Fickers M; Leyvraz S; Buyse M
Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(5):827-31.
1991: Calabresi F; Aapro M; Becquart D; Dirix L; Wils J; Ardizzoni A; Gerard B
Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(5):377-8.
1991: Wils J A
Perspectives in chemotherapy of advanced gastric cancer.
Anti-cancer drugs 1991;2(2):133-7.
1990: Wils J; Wagener D J
Adjuvant treatment of colon cancer: where to go from here?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1990;1(5):329-31.
1990: Coombes R C; Schein P S; Chilvers C E; Wils J; Beretta G; Bliss J M; Rutten A; Amadori D; Cortes-Funes H; Villar-Grimalt A
A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(8):1362-9.
1990: Bleiberg H; Vanderlinden B; Buyse M; Haegele P; Paillot B; Tagnon A; Wils J; Cartei G; Fornasiero A; Duez N
Randomized phase II study of a combination of cisplatin (DDP), 5-fluorouracil (5-FU), and allopurinol (HPP) versus 5-FU in advanced colorectal carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group study.
Cancer investigation 1990;8(5):471-5.
1990: Wils J A
Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center.
Oncology 1990;47(2):115-20.
1990: Wils J; Utama I; Sala L; Smeets J; Riva A
Phase II study of high-dose epirubicin in non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 1990;26(11-12):1140-1.
1989: De Pree N; Wils J
Chemotherapy consisting of cisplatin, doxorubicin and cyclophosphamide as an adjunct to surgery in stage Ic-II epithelial ovarian carcinoma. Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg.
Anticancer research 1989;9(6):1873-5.
1989: De Pree N; Wils J
Long-term survival of patients with advanced ovarian carcinoma treated with cisplatin-based chemotherapy regimens.
Anticancer research 1989;9(6):1869-71.
1989: Wils J; Bleiberg H; Buyse M; Wagener D T; Splinter T; Veenhof C; Herben M; Duez N
An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with ifosfamide in advanced adenocarcinoma of the pancreas. EORTC Gastrointestinal Group.
European journal of cancer & clinical oncology 1989;25(7):1119-20.
1989: Wils J; van Geuns H
Chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide as an adjunct to surgery in stage Ic-II epithelial ovarian carcinoma. Gynecologic Oncology Group of the Comprehensive Cancer Center.
American journal of clinical oncology 1989;12(3):251-4.
1989: Wils J; Bleiberg H
Current status of chemotherapy for gastric cancer.
European journal of cancer & clinical oncology 1989;25(1):3-8.
1988: Wils J; van Geuns H; Baak J
Proposal for therapeutic approach based on prognostic factors including morphometric and flow-cytometric features in stage III-IV ovarian cancer.
Cancer 1988;61(9):1920-5.
1988: Wils J A
Myeloprotective effect of high dose medroxyprogesterone acetate (MPA).
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1988;7(1):60-2.
1988: Wils J; Utama I; Smeets J
Chemotherapy consisting of epirubicin, cisplatin, and etoposide followed by irradiation in stage III non-small cell lung cancer and chemotherapy alone in stage IV non-small cell lung cancer.
Oncology 1988;45(6):413-6.
1987: Lacave A; Wils J; Bleiberg H; Diaz-Rubio E; Duez N; Dalesio O
An EORTC Gastrointestinal Group phase III evaluation of combinations of methyl-CCNU, 5-fluorouracil, and adriamycin in advanced gastric cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(9):1387-93.
1987: Wils J; Bleiberg H; Dalesio O; Duez N; Blijham G; Planting A; Splinter T; Weber W
An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with 5-fluorouracil in advanced adenocarcinoma of the pancreas.
European journal of cancer & clinical oncology 1987;23(7):1017-8.
1987: Wils J A
Current status of chemotherapy for advanced gastric cancer.
Anticancer research 1987;7(4B):755-9.
1986: Wils J; Bleiberg H; Dalesio O; Blijham G; Mulder N; Planting A; Splinter T; Duez N
An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(12):1799-803.
1986: Wils J; Blijham G; Naus A; Belder C; Boschma F; Bron H; Ceelen T; Eekhout A; von Erp J; Geelen P
Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(7):1068-73.
1985: Lacave A J; Wils J; Diaz-Rubio E; Clavel M; Planting A; Bleiberg H; Duez N; Dalesio O
cis-Platinum as second-line chemotherapy in advanced gastric adenocarcinoma. A phase II study of the EORTC Gastrointestinal Tract Cancer Cooperative Group.
European journal of cancer & clinical oncology 1985;21(11):1321-4.
1985: Wils J; Bleiberg H; Blijham G; Dalesio O; Duez N; Lacave A; Splinter T
Phase II study of epirubicin in advanced adenocarcinoma of the pancreas.
European journal of cancer & clinical oncology 1985;21(2):191-4.

Sign-in to see more